Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy

Area of Science:

• Oncology
• Biophysics
• Cancer Therapeutics

Background:

• A novel anti-cancer treatment integrating chemotherapeutic agents with a low electric field was developed.
• The study focused on evaluating the efficacy of this new treatment against prostate metastatic transgenic adenocarcinoma of mice (TRAMP).

Purpose of the Study:

• To investigate the efficacy of a combined chemotherapy and low electric field treatment against metastatic prostate cancer in a mouse model.
• To assess the impact of the treatment on tumor growth, survival rates, and the development of anti-tumor immunity.

Main Methods:

• Transgenic adenocarcinoma of mice (TRAMP) models with varying tumor sizes (5, 10, 13 mm) were treated with Low Electric Field Cancer Treatment-Enhanced Chemotherapy (LEFCT-EC) using doxorubicin.
• Tumor growth, survival, and the development of anti-tumor immunity and immunosuppression were monitored post-treatment.

Main Results:

• The electric field enhanced doxorubicin uptake by TRAMP cells in vitro.
• LEFCT-EC significantly reduced tumor size, prolonged survival, and achieved cure rates of 36-93% in vivo, depending on the initial tumor size.
• The LEFCT-EC treatment demonstrated superior effectiveness compared to surgery with or without chemotherapy.

Conclusions:

• Low Electric Field Cancer Treatment-Enhanced Chemotherapy (LEFCT-EC) shows significant promise as an effective method for destroying metastatic prostate tumors.
• The development of anti-tumor immunity and immunosuppression in cured animals warrants further investigation regarding long-term treatment effectiveness.